Skip to main content
SpringerLink
Log in

Die isolierte Extremitätenperfusion zur Behandlung von Weichteilsarkomen, Transitmetastasen des malignen Melanoms sowie anderen irresektablen Tumoren

  • Chapter
Book cover Regionale Tumortherapie

  • 42 Accesses

Zusammenfassung

Die Technik der isolierten Extremitätenperfusion unter Zuhilfenahme eines extrakorporalen Kreislaufes wurde von Creech et al. (1958) an der Tulane Universität in New Orleans entwickelt. Der Vorteil dieser Behandlungsart besteht darin, dass man hohe Zytostatikadosen in der tumortragenden Extremität erreicht, ohne systemische Nebeneffekte hervorzurufen. Die isolierte extrakorporale Extremitätenperfusion erlaubt damit 15- bis 20-mal höhere Zytostatikakonzentrationen im Vergleich zur systemischen Applikation (Benckhuisjsen 1988). Die Standardmedikation in diesem Behandlungsregime ist Melphalan (L-Phenyl-Alaninmustard).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Asher AL, Mule JJ, Reiehert CM, Shiloni E, Rosenberg SA (1987) Studies of the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138:963–974

    PubMed  CAS  Google Scholar 

  • Benckhuijsen C, Kroon BB, van Geel AN et al. (1988) Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 14:157–163

    PubMed  CAS  Google Scholar 

  • Biekels, J, Manusama, ER, Gutman M et al. (1999) Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity [In Process Citationl. Eur J Surg Oncol 25:509–514

    Article  Google Scholar 

  • Braat RP, Wieberdink J, van Slooten EA, Olthuis G (1983) Regional perfusion with Adriamyein in soft tissue sarcomas. In: Schwemmle K, Aigner K (eds) Vascular Perfusion in Cancer Therapy, Recent Results in Cancer Research search, vol 86, Springer, Berlin Heidelberg New York Tokyo, pp 260–263

    Chapter  Google Scholar 

  • Brouckaert PGG, Leroux-Rouls GG, Guisez Y Tavernier J, Fiers W (1986) In vivo anti-tumor activity of recombinant human and murine TNF, alone and in combination with IFN-gamma on a syngeneie murine melanoma. Int J Cancer 38:763–769

    Article  PubMed  CAS  Google Scholar 

  • Carswell EA, Old LJ, Kassel RL (1975) An endotoxin induced serum factor that causes necrosis of tumors. Proc Nat Acad Sei USA 72:3666–3370

    Article  CAS  Google Scholar 

  • Cavaliere R, Ciocatto RC, Giovanella BC et al. (1967) Selective heat sensitivity of cancer cells: Biochemical and clinical studies. Cancer 20:1351–1381

    Article  PubMed  CAS  Google Scholar 

  • Cavaliere R, Calabro A, Di Filippo F, Carlini S, Giannarelli D (1987) Prognosic parameters in limb recurrent melanoma treated with Hyperthermic antiblastic perfusion (abstract). Proceedings International Conference Regional Cancer Treatment, Ulm G7:163

    Google Scholar 

  • Clark J, Grabs AJ, Parsons PG, Smithers BM, Addison RS, Roberts MS (1994) Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusions of melanoma. Melanoma Research 4:365–370

    Article  PubMed  CAS  Google Scholar 

  • Creech DG (1958) Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Melanoma Res 4:616–632

    Google Scholar 

  • Dahl O, Mella O (1990) Hyperthermia and chemotherapeutic agents. In: Field SB, Hand JW (eds) An Introduction to the Practical Aspects of Hyperthermia. Taylor & Francis, London, pp 108–142

    Google Scholar 

  • DeWilt JHW, Manusama ER, van Tiel ST, van IJken MGA, ten Hagen TLM, Eggermont AMM (1999) Prerequisites for effective isolated limb perfusion using tumour necrosis factor-alpha and melphalan in rats. Br J Cancer 80:161–166

    Article  CAS  Google Scholar 

  • De Wilt JHW, ten Hagen TLM, de Boeck G, van Tiel ST, de Bruijn EA, Eggermont AMM (2000) Tumour Necrosis Factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 82:1000–1003

    Article  PubMed  Google Scholar 

  • DeWilt JHW, Manusama ER, van Etten B et al. (2000) Inhibition of Nitric Oxide Synthesis by L-NAME results in Synergistic antitumour activity with melpahlan and tumour necrosis factor-alpha-based isolated limb. Br J Cancer 83:1176–1211

    Article  CAS  Google Scholar 

  • De Wilt JHW, Bout A, Eggermont AMM et al. (2001) Adenoviru-mediated IL-3ß gene transfer using isolated limb perfusion inhibits growth of limb sarcoma in rats. Human Genetherapy 12:489–502

    Google Scholar 

  • Di Filippo F, Calabro A, Giannarelli D, Carlini S, Cavaliere F, Moscarelli F, Cavaliere R (1989) Prognostic variables in recurrent limb melanoma treated with Hyperthermic antiblastic perfusion Cancer 63:2551–2561

    Article  PubMed  Google Scholar 

  • Eggermont AMM, Liénard D, Schraffordt Koops H, Van Geel AN, Hoekstra HJ, Lejeune FJ (1992) Limb salvage by high dose tumor necrosis factor-alpha (TNF), gamma-interferon (IFN) and melphalan isolated limb per fusion (ILP) in patients with irresectable soft tissue sarcomas (abstract). Proc Am Soc Cin Oncol 11:412

    Google Scholar 

  • Eggermont AMM, Schraffordt Koops H, Lienard D, Lejeune FJ, Oukerk M Angiographie observations before and after high dose TNF isolated limb perfusion in patients with extremity soft tissue sarcomas. Eur J Surg Oncol 1994;20:323–324

    Google Scholar 

  • Eggermont AMM, Lienard D, Schraffordt Koops H at al. (1995) High dose tumor necrosis factor-a in isolation perfusion of the limb: highly effective treatment for melanoma in transit metastases or unresectable sarcoma. Reg Cancer Treat, 7:32–36

    Google Scholar 

  • Eggermont AM, Schraffordt Koops H, Lienard D et al. (1996) Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial [see comments]. J Clin Oncol 14:2653–2665

    PubMed  CAS  Google Scholar 

  • Eggermont AMM (1996) Treatment of melanoma intransit metastases confined to the limb. Cancer Surveys 26:335–349

    PubMed  CAS  Google Scholar 

  • Eggermont AM, Schraffordt Koops H, Klausner JM et al. (1996) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multi center European experience. Ann Surg 224:756–64, discussion 764-565

    Article  PubMed  CAS  Google Scholar 

  • Eggermont AMM, Schraffordt Koops H, Klausner JM et al. (1999) Limb Salvage by Isolation Limb Perfusion with Tumor Necrosis Factor Alpha and melphalan for locally advanced extremity soft tissue sarcomas: results of 270 perfusions in 246 patients (abstract). Proceed ASCO 11:497

    Google Scholar 

  • Fenn NJ, Horgan K, Johnson RC et al. (1997) A randomized controlled trial of prophylactic isolated cytotoxic perfusion for poor-prognosis primary melanoma of the lower limb. Eur J Surg Oncol 23:6–9

    Article  PubMed  CAS  Google Scholar 

  • Filippo FD, Calabro AM, Cavallari A et al. (1988) The role of Hyperthermic perfusion as a first step in the treatment of soft tissue sarcomas of the extremities. World J Surg 12:332–339

    Article  PubMed  Google Scholar 

  • Fraker DL, Alexander HR, Andrieh M et al. (1995) Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and highdose tumor necrosis factor. Cancer J Sci Am 1:122

    PubMed  CAS  Google Scholar 

  • Fraker DL, Alexander HR, Andrieh M, Rosenberg SA (1996) Treatment of patients with melanoma of the extremity using Hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 14:479–489

    PubMed  CAS  Google Scholar 

  • Franklin HR, Schraffordt Koops H, Oldhoff J et al. (1988) To perfuse or not to perfuse? A retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thiekness of 1.5 mm or greater. J Clin Oncol 6:701–708

    PubMed  CAS  Google Scholar 

  • Ghussen F (1989) Hyperthermic perfusion with chemotherapy in melanoma of the extremities. World J Surg 13:598–604

    Article  PubMed  CAS  Google Scholar 

  • Ghussen F, Nagel K, Groth W et al. (1984) A prospective randomized study of regional extremity perfusion in patients with malignant melanoma. Ann Surg 2000:764–768

    Google Scholar 

  • Hafström L, Rudenstam CM, Blomquist E et al. (1991) Regional Hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. J Clin Oncol 9:2091–2094

    PubMed  Google Scholar 

  • Hill S, Fawcett WJ, Sheldon J, Soni N, Williams T, Thomas JM (1993) Low dose tumor necrosis factor-alpha and melphalan in Hyperthermic isolated limb perfusion. Br J Surg 80:995–997

    Article  PubMed  CAS  Google Scholar 

  • Hoekstra HJ, Schraffordt Koops H, Molenaar WM, Oldhoff J (1987) Results of isolated regional perfusion in the treatment of malignant soft tissue tumors of the extremities. Cancer 60:1703–1707

    Article  PubMed  CAS  Google Scholar 

  • Hoekstra HJ, Schraffordt Koops H, de Vries IGE, van Weerden TW, Oldhoff J (1993) Toxicity of Hyperthermic isolated limb perfusion with eisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment. Cancer 72:1224–1229

    Article  PubMed  CAS  Google Scholar 

  • Jain RK (1994) Barriers to Drug Delivery in Solid Tumors. Scientific American 271:58–65

    Article  PubMed  CAS  Google Scholar 

  • Klaase JM, Kroon BBR, Benckhuysen C, Van Geel AN, Albus-Lutter ChE, Wieberdink J (1989) Results of regional isolation perfusion with cytostaties in patients with soft tissue tumors of the extremities. Cancer 64:616–621

    Article  PubMed  CAS  Google Scholar 

  • Klaase JM, Kroon BBR, Van Geel AN, Eggermont AMM, Franklin HR, Van Dongen JA (1993) A retrospective comparative study evaluating the results of a single perfusion versus a double perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb. Cancer 71:2990–2994

    Article  PubMed  CAS  Google Scholar 

  • Klaase JM, Kroon BBR, Van Geel AN, Eggermont AMM, Franklin HR, Hart AAM (1994) Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 115:39–45

    PubMed  CAS  Google Scholar 

  • Klaase JM, Kroon BBR, Van Wijk J, Van Geel AN, Eggermont AMM, Franklin HR, Hart AAM (1994) Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Col Surg 17:564–572

    Google Scholar 

  • Kettelhack Ch, Kraus Th, Hupp Th, Manner M, Schlag P (1990) Hyperthermic limb perfusion for malignant melanoma and soft tissue sarcoma. Eur J Surg Oncol 16:370–375

    PubMed  CAS  Google Scholar 

  • Klaase JM, Kroon BBR, Van Geel AN, Eggermont AMM, Franklin HR (1993) Systemic leakage during isolated limb perfusion for melanoma. Br J Surg 80:1124–1126

    Article  PubMed  CAS  Google Scholar 

  • Klaase JM, Kroon BBR, Eggermont AMM et al. (1995) A retrospective comparative study evaluating the results of “mild” Hyperthermic versus “controlled” normothermic perfusion for recurrent melanoma of the extremities. Eur J Cancer 31:73–81

    Article  Google Scholar 

  • Krementz ET, Carter RD, Sutherland CM, Hutton I (1977) Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg 185(5):555–564

    Article  PubMed  CAS  Google Scholar 

  • Krementz ET, Carter RD, Sutherland CM, Muchmore JH, Ryan RF, Creech O (1994) Regional chemotherapy for melanoma: a 35 year experience. Ann Surg 220:520–535

    Article  PubMed  CAS  Google Scholar 

  • Kristensen CA, Nozue M, Boucher Y, Jain RK (1996) Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Br J Cancer 74:533–536

    Article  PubMed  CAS  Google Scholar 

  • Kroon BBR, Klaase JM, Van Geel AN, Eggermont AMM (1992) Application of hyperhtmermia in regional isolated perfusion for melanoma of the limbs. Reg Cancer Treat 4:223–226

    Google Scholar 

  • Kroon BBR, Klaase JM, Van der Merwe SA, Van Dongen JA, Van der Zee J (1992) Results of a double perfusion schedule using high-dose hyperthermia and melphalan sequentially for recurrent melanoma of the limbs: A pilot study. Reg Cancer Treat 4:305–308

    Google Scholar 

  • Lejeune FJ, Deloof T, Ewalenko P (1983) Objective regression of unexcised melanoma in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan. Recent Results Cancer Res 86:268–276

    Article  PubMed  CAS  Google Scholar 

  • Lejeune FJ, Lienard D, Leyvraz S, Mirimanoff RO (1993) Regional therapy of melanoma. Eur J Cancer 29A:606–612

    Article  CAS  Google Scholar 

  • Lienard D, Ewalenko, Delmotte JJ, Renard N, Lejeune FJ (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10:50–62

    Google Scholar 

  • Lienard D, Eggermont AMM, Schraffordt Koops H et al. (1999) Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferongamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 9:491–502

    Article  PubMed  CAS  Google Scholar 

  • Lethi PM, Stephens MH, Janoff K, Stevens K, Fletcher WS (1986) Improved survival for soft tissue sarcoma of the extremities by regional hyperthermic perfusion, local excision and radiation therapy. Surg Gynecol Obstet 162:149–152

    Google Scholar 

  • Manda T, Nishigaki F, Mukumoto S, Masuda K, Nakamura T, Shimomura K (1990) The efficacy of combined treatment with recombinant human tumor necrosis factor-a and 5-fluorouracil is dependent on the development of capillaries in tumor. Eur J Cancer 26:93–99

    Article  PubMed  CAS  Google Scholar 

  • Manusama ER, Nooijen PTGA, Stavast J, Durante NMC, Marquet RL, Eggermont AMM (1996) Synergistic antitumour effect of recombinant human tumour necrosis factor a with melphalan in isolated limb perfusion in the rat. Br J Surg 83:551–555

    Article  PubMed  CAS  Google Scholar 

  • Manusama ER, Stavast J, Durante NMC, Marquet RL, Eggermont AMM (1996) Isolated limb perfusion in a rat osteosarcoma model: a new anti-tumour approach. Eur J Surg Oncol 22:152–157

    Article  PubMed  CAS  Google Scholar 

  • Manusama ER, Nooijen PTGA, Stavast J, de Wilt JHW, Marquet RL, Eggermont AMM (1998) Assessment of the role of neutrophils on the antitumor effect of TNF in an in vi vo isolated limb perfusion model in sarcoma-bearing brown norway rats. J Surg Res 78:169–175

    Article  PubMed  CAS  Google Scholar 

  • Manusama ER, de Wilt JHW, Hagen TLM ten, Marquet RL, Eggermont AMM (1999) Toxicity and antitumor activity of interferon-gamma alone and in combinations with TNF and Melphalan in isolated limb perfusion in the BN175 sarcoma tumor model in rats. Oncol Rep: 173–177

    Google Scholar 

  • Martijn H, Schraffordt Koops H, Milton GW et al. (1986) Comparison of two methods of treating primary malignant melanomas Clark IV and V, thickness 1.5 mm and greater, localized on the extremities. Wide surgical excision with and without adjuvant regional perfusion. Cancer 57:1923–1930

    Article  PubMed  CAS  Google Scholar 

  • McBride CM (1974) Sarcomas of the limbs: Result of adjuvant chemotherapy using isolation perfusion. Arch Surg 109:304–308

    Article  PubMed  CAS  Google Scholar 

  • McBride CM, Sugarbaker EV, Hickey RC (1975) Prophylactic isolation-perfusion as the primary therapy for invasive malignant melanoma of the limbs. Ann Surg 182:316–324

    Article  PubMed  CAS  Google Scholar 

  • Minor DR, Allen RE, Alberts D, Peng YM, Tardell G, Hutchinson J (1985) A clinical and pharmokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer 55:2638–2644

    Article  PubMed  CAS  Google Scholar 

  • Mule JJ, Asher A, Mclntosh J et al. (1988) Antitumor effect of recombinant tumor necrosis factor-a against murine sarcomas at visceral sites: tumor size influences the response to therapy. Cancer Immunol Immunother 26:202–208

    PubMed  CAS  Google Scholar 

  • Nooijen PTGA, Manusama ER, Eggermont AMM et al. (1996) Synergistic antitumour effects of TNF-α and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathologic, immunohistochemical and electron microscopic study. Br J Cancer 74:1908–1915

    Article  PubMed  CAS  Google Scholar 

  • Nooijen PTGA, Westphal JR, Eggermont AMM, Schalkwijk C, Max G, DeWaall RWM, Ruiter DJ (1998) Endothelial P-selectin expression is reduced in advanced primary melanoma and melanoma metastasis. Am J Pathol 152:679–682

    PubMed  CAS  Google Scholar 

  • Nooijen PTGA, Eggermont AMM, Schalkwijk L, HenzenLogmans S, DeWaal RMW, Ruiter DJ (1998) Complete response of melanoma in-transit metastasis after isolated limb perfusion with tumor necrosis factor-alpha and melphalan without massive tumor necrosis: clinical and histopathological study of the delayed-type reaction patterns. Cancer Res 58:4880–4887

    PubMed  CAS  Google Scholar 

  • Olieman AF, Lienard D, Eggermont AM, Kroon BB, Lejeune FJ, Hoekstra HJ, Koops HS (1999) Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multieenter study. Arch Surg 134:303–307

    Article  PubMed  CAS  Google Scholar 

  • Omlor G, Gross G, Ecker KW, Burger I, Feifel G (1993) Optimization of isolated hyperthermic limb perfusion. World J Surg 16:1117–1119

    Article  Google Scholar 

  • Posner M, Lienard D, Lejeune FJ, Rosenfelder D, Kirkwood JM (1994) Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor (TNF) alone for metastatic intransit melanoma. Proc Am Soc Clin Oncol 13:1351

    Google Scholar 

  • Renard N, Lienard D, Lespagnard L, Eggermont AMM, Heimann R, Lejeune FJ (1994) Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (TNF). Int J Cancer 57:656–663

    Article  PubMed  CAS  Google Scholar 

  • Renard N, Nooijen PTGA, Schalkwijk L et al. (1995) VWF release and platelet aggregation in human melanoma after perfusion with TNF. J Pathol 176:279–287

    Article  PubMed  CAS  Google Scholar 

  • de Roos WK, Wilt JHW de, Kaaden ME van der et al. (2000) lsolated limb perfusion for local gene delivery: efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas. Ann Surg 232:814–821

    Article  PubMed  Google Scholar 

  • Rosin RD, Westbury G (1980) Isolated limb perfusion for malignant melanoma. Practitioner 224:1031–1036

    PubMed  CAS  Google Scholar 

  • Rossi CR, Vecchiato A, Foletto M et al. (1994) Phase II study on neoadjuvant hyperthermic-antiblastie perfusion with doxorubicin in patients with intermediate of high grade limb sarcomas. Cancer 73:2140–2146

    Article  PubMed  CAS  Google Scholar 

  • Rossi CR, Foletto M, Di Filippo F et al. (1987) Soft tissue limb sarcomas: ltalian clinical trials with hyperthermic antiblastic perfusion. Cancer 86:1742–1749

    Article  Google Scholar 

  • Schiller JH, Bittner G, Storer B, Wilson JKV (1987) Synergistic antitumor effects of TNF and gamma-IFN on human colon carcinoma cell lines. Cancer Res 47:2809–2813

    PubMed  CAS  Google Scholar 

  • Schraffordt-Koops H, Vaglini M, Suciu S et al. (1999) Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group 8593. J Clin Oncol 16:2906–2912

    Google Scholar 

  • Sijens PE, Eggermont AMM, Van Dijk P, Oudkerk M (1995) 31p magnetic resonance spectroscopy as predictor for clinical response in human extremity sarcomas treated by single dose TNF + melphalan isolated limb perfusion. NMR in Biomedicine 18:215–224

    Article  Google Scholar 

  • Skene AI, Bulman AS, Williams TR, Meirion Thomas J, Westbury G (1990) hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br J Surg 77:765–767

    Article  PubMed  CAS  Google Scholar 

  • Spriggs DR, Sherman ML, Michie H (1988) Recombinant human tumor necrosis factor administered as a 24 h intravenous infusion. A phase land pharmacologic study. J Natl Cancer Inst 80:1039–1044

    Article  PubMed  CAS  Google Scholar 

  • Stehlin JS, de Ipolyi PD, Giovanella BC, Gutierrez AE, Anderson RF (1975) Soft tissue sarcomas of the extremity: Multidisciplinary therapy employing hyperthermic perfusion. Am J Surg 130:643–646

    Article  PubMed  Google Scholar 

  • Thomson JF, Gianoutsos MP (1992) Isolated limb perfusion for melanoma-effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 16:227–233

    Article  Google Scholar 

  • Vaglini M, Belli F, Ammatuna M et al. (1994) Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose TNF, gamma-IFN and melphalan. Cancer 73:483–492

    Article  PubMed  CAS  Google Scholar 

  • Veen van de AH, Wilt JHW de, Eggermont AMM, Tiel ST van, Hagen TLM ten (2000) TNF-a augments intratumoural concentration of doxorubicin in TNF-a-based isolated limb perfusion in rat sarcoma models and enhances antitumour effects. Br J Cancer 82:973–980

    Article  PubMed  Google Scholar 

  • Watanabe N, Niitsu Y, Umeno H (1988) Toxic effect of TNF on tumor vasculature in mice. Cancer Res 49:2179–2183

    Google Scholar 

  • Wieberdink K, Benckhuijsen C, Braat RP, Van Slooten EA, Olthuis GAA (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18: 905–910

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. A. M. M. Eggermont
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. L. M. ten Hagen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Chirurgie, Klinikum Chemnitz, Flemmingstraße 2, 09116, Chemnitz, Germany

    J. Boese-Landgraf

  2. Chirurgische Klinik, DRK-Krankenhaus Neuwied, Marktstraße 104, 56564, Neuwied, Germany

    Uwe Gallkowski

  3. Zentralinstitut für Diagnostische und Interventionelle Radiologie, Klinikum der Stadt Ludwigshafen, Bremserstraße 79, 67063, Ludwigshafen, Germany

    G. Layer

  4. Medizinische Klinik III, Klinikum Großhadern, Marchioninistraße 15, 81377, München, Germany

    A. Schalhorn

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Eggermont, A.M.M., ten Hagen, T.L.M. (2003). Die isolierte Extremitätenperfusion zur Behandlung von Weichteilsarkomen, Transitmetastasen des malignen Melanoms sowie anderen irresektablen Tumoren. In: Boese-Landgraf, J., Gallkowski, U., Layer, G., Schalhorn, A. (eds) Regionale Tumortherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-55839-9_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-55839-9_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-62602-9

  • Online ISBN: 978-3-642-55839-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation